NewsRx Logo Login/Signup
Home Newsletters Products Library About Us Contact -- Search NewsRx

NewsRx | Free Trials
Advertisement
VerticalNews | Global Warming
NewsRx | Free Newsletters
 
----------
------------
NewsRx on Facebook
-----
NewsRx Passes
Press Release Submissions
PR Login
-----
2008 Award Logo
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
-----
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

This website is certified by Health On the Net Foundation. Click to verify. This site complies with the HONcode standard for trustworthy health information:
verify here.

Security by Verisign

Immunotherapy


Return to Library

Free Immunotherapy Articles


Data on allergy medicine described by researchers at Ege University, Medical Department



2009 AUG 5 - (NewsRx.com) -- "IgG subclass deficiencies are common immune system disorders during childhood. The aim of this retrospective study was to review clinical findings and laboratory results of patients with IgG subclass deficiencies in order to determine the changes in serum IgG subclass levels during follow-up, the percentage and time span until normalization of the IgG subclass levels to age-corresponding normal levels, the type of infections incurred and the benefits of prophylaxis," scientists in Izmir, Turkey report.

"Among the 59 pediatric patients reviewed, the most frequent defect was an IgG3 subclass deficiency (77%). Nine percent of the patients had an isolated IgG2 deficiency and 14% had an IgG2+G3 deficiency. The most common clinical presentations were recurrent upper respiratory tract infections, followed by pneumonia, acute gastroenteritis and urinary tract infections. Atopy was present in 15% of the patients. Ninety percent of the patients were given a prophylactic treatment (benzathine penicillin, oral antibiotics, oral bacterial lysate or intravenous immunoglobulin). The frequency of recurrent infections decreased from 13.4 +/- 7.4 per year to 5.7 +/- 3.9 in patients receiving a prophylactic regimen. Serum IgG subclass levels reached normal ranges in 30% of the patients in the IgG3 deficiency group and in 35.7% of the patients in the IgG2+G3 deficiency group. with an isolated IgG2 deficiency did not reach age-related normal levels during the study period. Our study shows that IgG subclass levels may normalize in 30 to 40% of patients at about 6 years of age," wrote N.E. Karaca and colleagues, Ege University, Medical Department.

The researchers concluded: "We emphasize the need of monitoring IgG levels together with the clinical symptomatology in affected individuals and initiate preventive measures when appropriate.."

Karaca and colleagues published their study in Asian Pacific Journal of Allergy and Immunology (Clinical and Laboratory Evaluation of Periodically Monitored Turkish Children with IgG Subclass Deficiencies. Asian Pacific Journal of Allergy and Immunology, 2009;27(1):43-48).

For additional information, contact N. Kutukculer, Ege University, Faculty Medical, Dept. of Pediatrics, Division Pediatrics Immunology, Izmir, Turkey.

The publisher's contact information for the Asian Pacific Journal of Allergy and Immunology is: Allergy Immunology Society Thailand, Mahidol University, Dept. Microbiology Immunology, Faculty Tropical Med, Bangkok 10400, Thailand.

Keywords: Turkey, Izmir, Life Sciences, Acute Gastroenteritis, Urology, Urinary Tract Infection, Pediatric, Allergy Medicine, Allergies, Respiratory Tract Infections, Immunology, Allergy and Immunology, Ege University, Medical Department.

This article was prepared by Immunotherapy Weekly editors from staff and other reports. Copyright 2009, Immunotherapy Weekly via NewsRx.com.

NewsRx NewsRx NewsRx
-----------------------
PR Login